These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 28374321)
1. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer. Zapatero A; Roch M; Büchser D; Castro P; Fernández-Banda L; Pozo G; Liñán O; Martin de Vidales C; Cruz-Conde A; García-Vicente F Clin Transl Oncol; 2017 Sep; 19(9):1161-1167. PubMed ID: 28374321 [TBL] [Abstract][Full Text] [Related]
2. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997 [TBL] [Abstract][Full Text] [Related]
3. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Sveistrup J; af Rosenschöld PM; Deasy JO; Oh JH; Pommer T; Petersen PM; Engelholm SA Radiat Oncol; 2014 Feb; 9():44. PubMed ID: 24495815 [TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170 [TBL] [Abstract][Full Text] [Related]
5. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients. Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386 [TBL] [Abstract][Full Text] [Related]
6. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study. Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594 [TBL] [Abstract][Full Text] [Related]
7. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy. Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939 [TBL] [Abstract][Full Text] [Related]
8. Nomogram to predict rectal toxicity following prostate cancer radiotherapy. Delobel JB; Gnep K; Ospina JD; Beckendorf V; Chira C; Zhu J; Bossi A; Messai T; Acosta O; Castelli J; de Crevoisier R PLoS One; 2017; 12(6):e0179845. PubMed ID: 28640871 [TBL] [Abstract][Full Text] [Related]
9. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398 [TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444 [TBL] [Abstract][Full Text] [Related]
11. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer. Jereczek-Fossa BA; Maucieri A; Marvaso G; Gandini S; Fodor C; Zerini D; Riva G; Alessandro O; Surgo A; Volpe S; Fanetti G; Arculeo S; Zerella MA; Parisi S; Maisonneuve P; Vavassori A; Cattani F; Cambria R; Garibaldi C; Starzyńska A; Musi G; De Cobelli O; Ferro M; Nolè F; Ciardo D; Orecchia R Med Oncol; 2018 Nov; 36(1):9. PubMed ID: 30483899 [TBL] [Abstract][Full Text] [Related]
12. Incremental changes verses a technological quantum leap: the additional value of intensity-modulated radiotherapy beyond image-guided radiotherapy for prostate irradiation. Ratnayake G; Martin J; Plank A; Wong W J Med Imaging Radiat Oncol; 2014 Aug; 58(4):503-10. PubMed ID: 25243269 [TBL] [Abstract][Full Text] [Related]
13. A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Shimizuguchi T; Nihei K; Okano T; Machitori Y; Ito K; Karasawa K Int J Clin Oncol; 2017 Apr; 22(2):373-379. PubMed ID: 27778117 [TBL] [Abstract][Full Text] [Related]
14. A dose escalated fiducial marker-based image guided radical radiotherapy in locally advanced prostate cancers: A single institute experience from India. Gupta PK; Rastogi N; Maria Das KJ; Kumar S J Cancer Res Ther; 2023; 19(2):382-388. PubMed ID: 37006073 [TBL] [Abstract][Full Text] [Related]
15. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity. Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581 [TBL] [Abstract][Full Text] [Related]
16. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Al-Mamgani A; Heemsbergen WD; Peeters ST; Lebesque JV Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):685-91. PubMed ID: 18718725 [TBL] [Abstract][Full Text] [Related]
17. Image-guided intensity-modulated radiotherapy of prostate cancer: Analysis of interfractional errors and acute toxicity. Rudat V; Nour A; Hammoud M; Alaradi A; Mohammed A Strahlenther Onkol; 2016 Feb; 192(2):109-17. PubMed ID: 26545764 [TBL] [Abstract][Full Text] [Related]
18. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783 [TBL] [Abstract][Full Text] [Related]
19. Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance. Nakamura K; Mizowaki T; Inokuchi H; Ikeda I; Inoue T; Kamba T; Ogawa O; Hiraoka M Int J Clin Oncol; 2018 Feb; 23(1):158-164. PubMed ID: 28756594 [TBL] [Abstract][Full Text] [Related]
20. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]